Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments
U Testa, G Castelli, E Pelosi - Medical Sciences, 2020 - mdpi.com
Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …
million new cases in world in 2018. It is the second leading cause of death from cancer in …
Neoadjuvant chemotherapy for breast cancer: past, present, and future
M Asaoka, S Gandhi, T Ishikawa… - Breast cancer: basic …, 2020 - journals.sagepub.com
Neoadjuvant chemotherapy (NAC) had been developed as a systematic approach before
definitive surgery for the treatment of locally advanced or inoperable breast cancer such as …
definitive surgery for the treatment of locally advanced or inoperable breast cancer such as …
CD8 T cell score as a prognostic biomarker for triple negative breast cancer
CD8 T cell is an essential component of tumor-infiltrating lymphocytes (TIL) and tumor
immune microenvironment (TIME). Using the xCell CD8 T cell score of whole tumor gene …
immune microenvironment (TIME). Using the xCell CD8 T cell score of whole tumor gene …
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
Tumor associated macrophages (TAMs) play a critical role in biology of various cancers,
including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” …
including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” …
G2M cell cycle pathway score as a prognostic biomarker of metastasis in estrogen receptor (ER)-positive breast cancer
The vast majority of breast cancer death is a result of metastasis. Thus, accurate
identification of patients who are likely to have metastasis is expected to improve survival …
identification of patients who are likely to have metastasis is expected to improve survival …
MYC targets scores are associated with cancer aggressiveness and poor survival in ER-positive primary and metastatic breast cancer
MYC is one of the most studied oncogenes that is known to promote cell proliferation. We
utilized MYC targets v1 and MYC targets v2 scores of gene set variation analysis and …
utilized MYC targets v1 and MYC targets v2 scores of gene set variation analysis and …
Abundance of regulatory T cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer
Simple Summary Regulatory CD4+ T cell (Treg) is one of the suppressive immune cells, but
data on its clinical relevance in large human breast cancer cohort is limited. Abundance of …
data on its clinical relevance in large human breast cancer cohort is limited. Abundance of …
The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+/HER2− breast cancer
E2F transcription factors play critical roles in the cell cycle. Therefore, their activity is
expected to reflect tumor aggressiveness and responsiveness to therapy. We scored 3905 …
expected to reflect tumor aggressiveness and responsiveness to therapy. We scored 3905 …
[HTML][HTML] KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival
KRAS signaling is associated with cancer progression in several cancers. Upregulation of
KRAS signaling is often seen in cancers that harbor high KRAS mutation rate, such as …
KRAS signaling is often seen in cancers that harbor high KRAS mutation rate, such as …
Plasmacytoid dendritic cell (pDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) …
Simple Summary Dendritic cells (DC) represent a major antigen-presenting cell in the tumor
immune microenvironment (TIME) and play an essential role in cancer immunity. Clinical …
immune microenvironment (TIME) and play an essential role in cancer immunity. Clinical …